Table 2.
Predictor | DSS success | DSS positive effects | DSS negative effects | Objective discontinuation | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|
b | t | R2 | b | t | R2 | b | t | R2 | OR | z | |
Sociodemographic data | |||||||||||
Age | 0.01 | 0.13 | <0.001 | 0.02 | 0.24 | 0.001 | −0.09 | −1.08 | 0.012 | 0.99 | −0.69 |
Gender (female v. male) | −0.16 | −0.14 | <0.001 | −3.46 | −1.59 | 0.027 | 0.07 | 0.03 | <0.001 | 0.31* | −2.33 |
Education (high v. low) | 0.02 | 0.02 | <0.001 | −0.65 | −0.30 | 0.001 | −2.45 | −1.25 | 0.017 | 0.76 | 0.62 |
Clinical and medication history | |||||||||||
Duration of disorder | −0.01 | −0.17 | <0.001 | 0.12 | 0.90 | 0.008 | −0.02 | −0.13 | <0.001 | 1.00 | 0.14 |
Discontinuation of 1st gen AP | −1.03 | −0.93 | 0.009 | −2.38 | −1.06 | 0.012 | 4.05* | 2.01 | 0.042 | 0.74 | −0.64 |
Discontinuation of 2nd gen AP | 1.14 | 0.74 | 0.006 | 6.74* | 2.19 | 0.049 | −6.95* | −2.51 | 0.064 | 2.40 | 1.32 |
Duration of medication intake | 0.06 | 0.85 | 0.008 | 0.16 | 1.15 | 0.014 | −0.05 | −0.44 | 0.002 | 0.99 | −0.26 |
Multiple discontinued drugs (v. one) | −0.32 | −0.32 | 0.001 | −1.05 | −0.51 | 0.003 | 4.33* | 2.41 | 0.060 | 0.57 | −1.33 |
Concomitant medication | 0.98 | 0.81 | 0.007 | −0.92 | −0.37 | 0.001 | 0.93 | 0.42 | 0.002 | 0.76 | 0.54 |
Professional support | |||||||||||
Shared decision-making | 0.06 | 1.43 | 0.022 | −0.43 | −0.75 | 0.006 | −0.06 | −0.75 | 0.006 | 0.98 | −1.39 |
Therapeutic alliance | 0.18 | 0.64 | 0.004 | −0.42 | −0.75 | 0.006 | −0.06 | 0.13 | <0.001 | 0.69** | −0.37 |
Psychotherapy during attempt | −0.30 | −0.30 | 0.001 | −4.15* | −2.07 | 0.045 | 3.31+ | 1.81 | 0.034 | 0.79 | −0.55 |
Circumstances | |||||||||||
Unstable situation | −0.01 | −0.28 | 0.001 | −0.16 | −1.53 | 0.024 | 0.27** | 2.92 | 0.085 | 1.05* | 1.97 |
Discontinuation strategy | |||||||||||
Preparation | 1.12* | 2.17 | 0.049 | 1.32 | 1.23 | 0.016 | −2.14* | 2.25 | 0.052 | 0.71 | −1.49 |
Followed a tapering plan | 0.48 | 1.07 | 0.012 | −0.58 | −0.63 | 0.004 | −0.50 | −0.59 | 0.004 | 0.74 | −1.50 |
Adjustment phasesa | 1.20** | 2.84 | 0.098 | 2.44** | 2.79 | 0.094 | −3.02*** | 3.98 | 0.174 | 1.02 | 0.10 |
Flexible reductiona | −0.82+ | −1.80 | 0.042 | 1.59+ | 1.69 | 0.037 | 0.85 | 0.99 | 0.013 | 1.54* | 2.03 |
Accelerated pacing (v. slow)a | −1.20 | −0.89 | 0.013 | −4.56 | −1.56 | 0.039 | 1.47 | 0.57 | 0.005 | 0.51 | −1.07 |
Coping strategies | |||||||||||
Physical care | −1.30* | −2.43 | 0.061 | 1.18 | 1.04 | 0.012 | 0.98 | 0.95 | 0.010 | 0.81 | −0.91 |
Relaxation | 0.40 | 0.61 | 0.004 | 4.99*** | 3.91 | 0.145 | 2.17+ | −1.75 | 0.033 | 1.10 | 0.33 |
Mindful awareness | 1.73*** | 3.96 | 0.150 | 3.88*** | 4.27 | 0.168 | −3.25*** | −3.85 | 0.141 | 0.89 | −0.59 |
Self-compassion | 0.23 | 0.44 | 0.002 | 3.45** | 3.36 | 0.112 | −1.91+ | −1.96 | 0.041 | 0.98 | −0.07 |
Supportive relationships | 1.38* | 2.60 | 0.071 | 3.74*** | 3.55 | 0.123 | −4.22*** | −4.57 | 0.188 | 0.77 | −1.13 |
Supportive structures | 0.88 | 1.61 | 0.028 | 4.41*** | 4.15 | 0.161 | −3.58*** | 3.62 | 0.127 | 0.84 | −0.71 |
Drug consumption | −0.50 | 1.16 | 0.015 | 0.58 | 0.64 | 0.005 | 0.98 | 1.19 | 0.016 | 1.52+ | 1.90 |
Note: Regression analyses with one predictor and one dependent variable.
Only participants who indicated to have followed a tapering plan responded to the questions on the details of the tapering plan (n = 76).
+p < 0.1, *p < 0.05, **p < 0.01, ***p < 0.001. Significant effects are printed in bold.